



Egyptian Int. Pharmaceutical Industries Co. S.A.E



Board of Directors Report For the Financial Period January/September 2023 (Consolidated Statements)

We present the Board of Directors' report on the consolidated financial statements for the period from January 1, 2023, to September 30, 2023, for the Egyptian International Pharmaceutical Industries Company (EIPICO).

Company Overview:

Purpose: EIPICO engages in pharmaceuticals, medical products, cosmetics, chemicals, veterinary products, pesticides, dietary supplements, medical plants, special foods, glass ampoule manufacturing, and plastic pharmaceutical packaging. It operates within and beyond Egypt.

The duration of the company has been extended to twenty-five years, commencing from December 18, 2005, and ending on December 17, 2030, with the possibility of renewal for a similar period by a decision of the Extraordinary General Assembly.

The company is subject to Law No. 43 of 1974, as amended by Law No. 32 of 1977.

Key Data:

Authorized Capital: EGP 1,500,000,000

Paid-Up Capital: EGP 1,487,557,500

Issued Capital: EGP 1,487,557,500

Nominal Value per Share: EGP 10

Commercial Registry Number and Date: 11116, December 3, 1980

- The issued capital has been increased from EGP 991,705,000 to EGP 1,487,557,500, representing an increase of EGP 495,852,500 distributed over 49,585,250 shares, as per the Commercial Register dated August 6, 2023.

✓





significant achievements:

1. Net Sales (Revenue):

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Domestic Market Net Sales	2223	1733	489.5	28.2%
Tender Sales Net Sales	319	265	55	20.1%
Export Net Sales	1133	685	448	65.5%
Toll Sales to Others	6.1	4.5	1.6	35.7%
Total Company Net Sales	3681	2687	994	36.9%

2.

Cost of Goods Sold:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cost of Goods Sold	1979	1508	471.1	31.3%
Cost of Goods Sold to Net Sales	54%	56%	(2%)	

3. Production:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Production Value	4177	3063	1114	36%





Egyptian Int. Pharmaceutical Industries Co. S.A.E



4. Profitability:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Gross Profit	1702	1179	523	44%
Net Profit Before Tax	853	546	307	56%
Net Profit After Tax	644	418	226	54%

5. Assets under construction:

Category	During the Period (Million EGP)	December 31, 2022 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Assets under construction	2880	866	2014	233%

6. Cash Flows and Cash Balances:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cash Flows from Operations	(100)	(169)	70	(41%)
Cash Flows from Investing	(2124)	(340)	1784	525%
Cash Flows from Financing	2186	586	1600	273%
Net Cash Flow for the Period	(38)	76	(115)	(150%)
Exchange Rate Impact on Cash	221	103	118	114%
Cash Balance at the Beginning	483	312	171	55%



Egyptian Int. Pharmaceutical Industries Co. S.A.E



Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cash Balance at the Beginning	483	312	171	55%
Cash Balance on June 30, 2023	666	491	175	36%

7. Capital:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Capital	1487.5	991.705	495.8	50

8. Treasury Shares:

Category	During the Period (Million EGP)	December 31, 2022 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Treasury Shares	0	0	0	0

9. Equity (Including Surplus of the Period):

Category	During the Period (Million EGP)	December 31, 2022 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Equity (Including Surplus)	4081.6	3242.3	839.3	26%

Accept our sincere regards and respect.

Chairman and Managing Director

Dr. Ahmed Kelani



A. Kelani 13
11/23